Biomedical subjects
Publications and source records attributed to Z Wójcik.
The care of patients with acute pancreatitis is complex. This review summarizes the etiopathogenesis, prognosis, nonoperative management of patients with acute pancreatitis, the importance of nutrition in patients with severe acute pancreatitis and the role of monitoring and rationale of endoscopic and surgical intervention.
They presented a valuation of exocrine pancreatic function using pancreolaurinic test in 15 patients with chronic pancreatitis and in 34 patients after acute pancreatitis. In all patients with chronic pancreatitis they noted an insufficiency of exocrine pancreatic function with association of disorders of tolerance for carbohydrates during a year after a Puestow's operation. They noted a handicap of exocrine pancreatic function in 42% patients just after acute pancreatitis, in 18% patients a year acute pancreatitis and in 26% patients after 2-6 years from illness with association of disorders of tolerance for carbohydrates.
Fifteen patients with chronic pancreatitis were qualified for surgical treatment on the basis of the results of endoscopic retrograde cholangiopancreatography, pancreolauryl test and glucose tolerance test. Significant changes according to Cambridge scale correlated with exocrine-endocrine pancreatic failure. In patients with Wirsung duct of diameter above 6 mm Puestow operation was performed while in patients with narrow Wirsung duct resection procedures were carried out. Control examinations carried out one year after Puestow operation demonstrated in all 10 patients lack of improvement both in the exocrine and endocrine pancreatic function. In 70% of the patients after anastomotic operation and in 80% of the patients after resections, complete regression of preoperative pain was observed.
The purpose of the work as an assessment of the effectiveness of cefazolin (Kefzol) in preventing infections in patients after abdominal surgery. The prospective studies included 200 patients, out of whom in 100 patients in the studied group Kefzol was administered prior to and for 24 hours after operation, while in 100 patients in the control group no prevention was used. The percent of infections in the studied group was lower in comparison to the control group (9% vs 25%, p < 0.01). A statistically significant reduction was obtained of wound infection per cent from 19% in the control group to 7% in the studied group, including a reduction from 14.3% to 3.1% after operations on the gall bladder and bile ducts, and from 18.2% to 11.1% after gastroduodenal operations. The per cent of wound infections after appendectomy was 5.9% in the patients from the studied group receiving prophylactically Kefzol with metronidazole, and 20.6% in the patients from the control group. Bacteriological investigations, demonstrated that 87.5% bacterial strains were susceptible to cefazolin. In the authors' opinion cefazolin (Kefzol) is effective in the prevention of purulent complications, and the reduction of the per cent of infections causes lowering of treatment cost.
An analysis of infection incidence within one year after completion of the treatment for the acute lymphoblastic leukemia was performed in the group of 24 children. Infections incidence was related to the selected immunological parameters, mainly T4 and T8 lymphocyte subpopulations assayed with monoclonal antibodies. T4/T8 cells ratio (Ix) was determined. It was found that moderate decrease in the total lymphocyte count and Ix exist in children one year after completion of the treatment. This index is more significantly lower in children with more frequent infections while the absolute numbers of T4 and T8 lymphocytes are relatively increased. The obtained results suggest that no significant immunosuppression is observed in children affecting the number and the course of infections.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.